Astronomers just found the universe's ‘missing matter'
There's been a lot of discussion over the years about what the universe is made up of. While some argue that dark matter is holding it together, while others argue dark matter doesn't exist, despite us possibly detecting dark matter a time or two. What is more intriguing, though, is that astronomers believe the universe is missing matter, and now they say they've found evidence of it.
This matter was considered 'missing' because of how thinly it was spread among the various galaxies and halos of the universe. Because it is so diffuse, it's exceptionally hard to account for. But in a new study published in Nature Astronomy, astronomers from Caltech and the Center for Astrophysics | Harvard & Smithsonian (CfA) say they have detected the matter.
Today's Top Deals
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
Additionally, they say that they've thoroughly accounted for all the universe's missing matter. According to a statement shared by Caltech, the researchers relied on fast radio bursts (FRBs) to help illuminate the matter that lies between those distant FRBs and us here on Earth.
'The FRBs shine through the fog of the intergalactic medium, and by precisely measuring how the light slows down, we can weigh that fog, even when it's too faint to see,' Liam Connor, an assistant professor at Harvard and lead author on the new study explained. In total, the team looked at 69 FRBs, ranging in distance from around 11.74 million to 9.1 billion light-years away from us. FRB 20230521B, which is located 9.1 billion light-years away, is now the most distant FRB ever recorded.
Despite having detected more than a thousand FRBs, we've only managed to pinpoint around one hundred or so to their specific host galaxies. Other attempts to detect the missing matter had only hinted at its existence hiding among the holes and halos of the universe. However, by relying on the FRBs, the researchers were able to find evidence of the matter.
These findings will help us better understand the universe and how galaxies grow. They could also help us unravel some of the greatest mysteries of the early universe, including how the universe expanded has expanded so quickly since the Big Bang. And researchers say this is just the beginning of the use of FRBs in cosmology. A future radio telescope from Caltech will help find and localize up to 10,000 FRBs per year, which should dramatically enhance our understanding of these distant radio bursts.
More Top Deals
Amazon gift card deals, offers & coupons 2025: Get $2,000+ free
See the
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins
Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter. Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. View more earnings on TEM 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests,' Lefkofsky said in a statement on Friday. Database Update Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced. As a result, the company's database stands at over 350 petabytes of connected clinical and molecular data. Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter. Outlook Tempus AI increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion. Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business. The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024. Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July. Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction. Price Action: Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday. Read Next:Photo by Piotr Swat via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
10 minutes ago
- Yahoo
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call. Following the prepared remarks, there will be a Q&A session with the investment community. Participants are encouraged to submit their questions in advance of the call by sending them to: q@ Questions should be submitted by 10:00 a.m. Eastern Time on August 12, 2025. The investment community may participate in the conference call by dialing the following numbers: Investor dial in:U.S. Toll Free: 877-545-0320 International: 973-528-0002 Participant Access Code: 601260 Webcast URL: Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available until August 28, 2026. Teleconference Replay Number: Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 52831 About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" - a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. CONTACTS Investors:Michael Wood Phone: +1 646-597-6983 mwood@ Media:Uri Yablonka, Chief Business Officer Phone: +1 917-284-2911 uri@ Logo - View original content: SOURCE BrainStorm Cell Therapeutics Inc.
Yahoo
10 minutes ago
- Yahoo
RBL LLC secures investment from Modi Ventures
- Strategic investment to support RBL's mission to launch and scale breakthrough startups - Founder and general partner of Modi Ventures, Sahir Ali, to join RBL board of directors - Modi Ventures' Ali, RBL managing partner Wotton to speak on venture creation at Canaccord Genuity Growth Conference Aug. 12 HOUSTON, Aug. 8, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies, announced that it has secured an investment from Modi Ventures to support its mission to launch and scale breakthrough startups into clinical-stage companies. In addition, RBL has announced the appointment of Sahir Ali to its board of directors. Ali is the founder and current general partner of Modi Ventures, a leading venture capital firm investing in biology and technology based in Houston. Ali's experience as an accomplished technology and health care leader, investor and adviser will be instrumental in bridging the gap between academic biotech discoveries and the clinical care market. "This investment by Modi Ventures will be instrumental to RBL's growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups," said Paul Wotton, RBL's managing partner. "Sahir's addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission." "The bold thinking and entrepreneurial initiatives coming out of RBL represent an important cornerstone of the rapidly evolving Houston life sciences scene, and I am honored to contribute to this growth by joining this exceptional board," Ali said. "Partnering my new role at RBL with the investment made by Modi can truly help not only build companies but also shape the future of patient care in a collaborative and more efficient way." "Modi Ventures' investment is a strong signal of market validation for the acceleration model we've built into RBL," said Paul Cherukuri, board member of RBL and chief innovation officer of Rice University. "It reflects growing investor confidence in RBL's ability to turn breakthrough science into real-world therapies and in Houston's rise as a global force in biotech innovation." Modi Ventures employs a proprietary financial engineering framework grounded in modern portfolio theory and efficient frontier principles. With $134 million under management, Modi Ventures backs category-defining companies advancing artificial intelligence (AI)-driven drug discovery, diagnostics and engineered therapeutics. The firm also invests in leading funds across the biotech and technology spectrum. A parallel entrepreneur, scientist and innovator, Sahir has led transformative work and built companies across AI, cloud computing and precision medicine. Sahir serves on the board of directors of the Drug Information Association, a leading global life science membership association driving collaboration in drug, device and diagnostics development in pursuit of a healthier world. Sahir will join existing board members Wotton, Cherukuri, Omid Veiseh, Rima Chakrabarti, John Jaggers, Devyn Smith and James Watson, an accomplished group of leaders with deep expertise in biotech innovation, clinical translation and venture building who together provide strategic guidance to help drive RBL's continued growth and success. Wotton and Ali will participate in a panel discussion at the Canaccord Genuity 45th annual Growth Conference Aug. 12 to discuss the future of biotech venture creation and the evolving role of academic innovation in company formation. About RBL LLC: RBL LLC is a pioneering biotech venture creation studio based in Houston that is dedicated to accelerating the development of breakthrough medical technologies and therapies through company formation. RBL provides entrepreneurs, researchers and innovators with infrastructure, financial support and strategic guidance as well as access to laboratory space and shared resources in the Texas Medical Center Helix Park. For more information, please visit Media Contact: Russo PartnersDavid Schull or Liz Phillips(347) View original content: SOURCE RBL LLC
